Valuation: Atara Biotherapeutics, Inc.

Market Cap 85.92M 75.41M 70.89M 64.81M 121M 8.23B 122M 851M 330M 4.2B 323M 316M 13.61B P/E 2026 *
-8.65x
P/E 2027 * 7.21x
Enterprise Value 85.92M 75.41M 70.89M 64.81M 121M 8.23B 122M 851M 330M 4.2B 323M 316M 13.61B EV / Sales 2026 *
30.2x
EV / Sales 2027 * 2.1x
Free-Float
83.2%
Yield 2026 *
-
Yield 2027 * -
1 day-4.14%
1 week-15.33%
Current month-3.82%
1 month-11.75%
3 months-23.30%
6 months+76.68%
Current year-52.68%
1 week 8.4
Extreme 8.4
10.19
1 month 8.4
Extreme 8.4
11.33
Current year 3.92
Extreme 3.92
19.14
1 year 3.92
Extreme 3.92
19.14
3 years 3.92
Extreme 3.92
45.75
5 years 3.92
Extreme 3.92
501
10 years 3.92
Extreme 3.92
1,361.25
Manager TitleAgeSince
Chief Executive Officer 53 2024-09-08
Director of Finance/CFO 61 2026-06-25
Investor Relations Contact - 2023-06-30
Director TitleAgeSince
Director/Board Member 62 2014-02-28
Director/Board Member 66 2015-11-22
Director/Board Member 53 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Buy

Director

104,166 1.0377%
8/17/26 Sell

Chief Executive Officer

-5,062 0.0562%
7/22/26
Redmile Group LLC
ExerciceCompany 390,482 4.3338%
Change 5-day change 1-year change 3-year change Capi.($)
-4.14%-15.33%-34.00%-80.87% 89.64M
+0.06%+6.49%+60.29%+111.13% 74.27B
-2.29%-1.51%+33.30%+75.07% 61.21B
-2.05%-3.46%-18.60%+352.20% 26.38B
-2.39%+2.74%+0.19%-5.91% 25.34B
+0.57%+3.66%+25.59%-9.37% 20.84B
+1.29%-2.49%+152.11%+333.06% 15.17B
-2.44%-0.09%+42.50%+164.11% 14.41B
-3.91%-4.91%-14.10%+779.68% 13.66B
-1.12%-3.04%+15.72%+234.56% 11.99B
Average -1.64%-1.50%+26.30%+195.37% 26.34B
Weighted average by Cap. -1.22%+1.00%+35.98%+162.01%

Financials

2026 *2027 *
Net sales 2.85M 2.5M 2.35M 2.15M 4.02M 273M 4.05M 28.23M 10.94M 139M 10.7M 10.46M 451M 40.87M 35.87M 33.72M 30.83M 57.6M 3.91B 58.03M 405M 157M 2B 153M 150M 6.47B
Net income -14.62M -12.83M -12.06M -11.03M -20.61M -1.4B -20.76M -145M -56.17M -714M -54.9M -53.7M -2.32B 18.66M 16.37M 15.39M 14.07M 26.3M 1.79B 26.49M 185M 71.67M 911M 70.06M 68.52M 2.95B
Net Debt - -
Logo Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Employees
10
Date Price Change Volume
26-09-23 US$8.560 -4.14% 40,472
26-09-22 US$8.930 -4.80% 27,265
26-09-21 US$9.380 -3.20% 29,670
26-09-18 US$9.690 -0.21% 37,766
26-09-17 US$9.710 -3.96% 26,421
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.560USD
Average target price
13.67USD
Spread / Average Target
+59.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATRA Stock